Samsung Bioepis declares W104.3b interim cash dividend to parent Samsung Epis Holdings

Samsung Bioepis will pay an interim cash dividend of 104.3 billion won ($78 million) to its parent company, Samsung Epis Holdings, which holds a 100 percent stake in the biotech firm.

Samsung Epis Holdings disclosed Thursday that its subsidiary Samsung Bioepis approved the dividend — totaling 104.31 billion won, or 5,043 won per common share — through a board resolution on Wednesday.

The record date for the dividend is Dec. 4, with payment scheduled for Dec. 18. As an unlisted company, Samsung Bioepis did not calculate a market dividend yield, and the payout does not involve differential dividends.

The entire dividend will go to Samsung Epis Holdings, which owns 100 percent of Samsung Bioepis' issued shares. Samsung Bioepis accounts for 97.42 percent of Samsung Epis Holdings' total assets, based on the parent's separate financial statements as of end-2025, making it the holding company's core subsidiary.

The company said the dividend was a routine capital distribution carried out in accordance with commercial law and its articles of incorporation, based on Samsung Bioepis' earnings.

Samsung Epis Holdings had announced at the time of its corporate split last year that it planned to use dividends from its subsidiary as the holding company's primary source of funding.

Samsung Epis Holdings said it will deploy the dividend proceeds to support stable operations and strengthen financial flexibility under the holding company structure, while also reviewing investment opportunities to secure future growth in new drugs and biosimilars.